Principal Investigators

    Dr Rosemary Fricker

    Institution

    Keele University

    Contact information of lead PI

    Country

    United Kingdom

    Title of project or programme

    Re-creating the basal ganglia circuitry in a dish: Towards a model for developing therapies for Parkinson's

    Source of funding information

    Parkinson's UK

    Total sum awarded (Euro)

    € 40,674

    Start date of award

    01/01/2014

    Total duration of award in years

    2

    Keywords

    Research Abstract

    There is a lack of in vitro models of neurodegeneration in Parkinson’s that allow for functional measurement of the neuronal circuitry involved, and easy, reliable manipulation, to give accurate read-outs for screening new therapies. This innovative project aims to construct a replica of the basal ganglia circuitry affected in Parkinson’s by culturing specific neuronal subtypes within a Bio-MEMS microfluidic device. We will construct a device with separate chambers for four classes of neurons: midbrain dopamine neurons, striatal neurons, pallidal neurons and cortical neurons; each generated from dissected embryonic CNS tissue. The chamber containing striatal neurons will be connected to all other chambers using graduated microchannels, to allow unidirectional axonal afferents to grow in from the cortical and midbrain neurons, and for efferent projections from the striatal neurons to grow out into the chamber containing pallidal neurons. Thus we will create and interconnect the key nuclei of the basal ganglia.We aim to assess the function of this neuronal circuit by measuring neuronal function at the population level, using aluminium microelectrodes embedded within the base of the Bio-MEMS device. We will compare electrical activity with calcium imaging to assess neuronal responses within the circuit, to optimise accuracy/reliability of our system and to assess changes in neuronal activity with pharmacological stimulation/blockade. Establishing this novel in vitro model aims to lay the foundations to investigate neurodegeneration, to develop a more sustainable model using stem cell-derived neurons, and to become a high-throughput screening tool for emerging therapies.

    Further information available at:

Types: Investments < €500k
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF